The added benefit of a dedicated neck F-18 FDG PET-CT imaging protocol in patients with suspected recurrent differentiated thyroid carcinoma

Clinical Nuclear Medicine

Volumn 33, Issue 7, 2008, Pages 464-468

  Davison, Jonathan M ^a,b   Stocker, Derek J ^a,b   Montilla Soler, Jaime L ^a,b   Jurgens, Jennifer S ^a,b   Allen, Thomas W ^a,b   Holley, Timothy S ^a,b   Stack, Aaron L ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Delayed imaging; FDG; PET CT; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; CONTRAST MEDIUM; DNA; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; IMAGE ANALYSIS; NECK; RECURRENT CANCER; RETROSPECTIVE STUDY; SOFT TISSUE DEFECT; THYROID CARCINOMA; CARCINOMA; CELL DIFFERENTIATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE; WHOLE BODY IMAGING;

CARCINOMA; CELL DIFFERENTIATION; CONTRAST MEDIA; DNA; FLUORODEOXYGLUCOSE F18; HUMANS; NECK; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECURRENCE; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 52249120408     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31817792c9     Document Type: Article

References (13)

1. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9:421-427.
2. Stokkel M, Duchateau C, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imag. 2006;50:78-87.
3. Wilson PC, Millar BM, Brierley JD. The management of advanced thyroid cancer. Clin Oncol. 2004;16:561-568.
4. Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med. 36:194-205.
5. Schulter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131i scan. J Nucl Med. 2001;42:71-76.
6. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47:616-624.
7. Halpern BS, Dahlbom M, Auerbach M, et al. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med. 2005;46:603-607.
8. Nahas BS, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope. 2005;115: 237-243.
9. Robbins RJ, Wan Q, Grewal RK, et al. Real time prognosis for metastatic thyroid carcinoma based on 2-[18f]fluoro-2-deoxy-d-glucosepositron emission tomography scanning. J Clin Endocrinol Metabol. 2006;91:498-505.
10. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur JNucl Med. 1999;26:1345-1348.
11. Kazuo K, Masatoshi I, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumor detection. Eur J Nucl Med. 2001;28: 696-703.
12. Demura Y, Tsuchida T, Ishizaki T, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540-548.
13. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metabol. 1999;84:3877-3885.